1. Home
  2. NCNA vs NDRA Comparison

NCNA vs NDRA Comparison

Compare NCNA & NDRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NuCana plc

NCNA

NuCana plc

HOLD

Current Price

$3.72

Market Cap

7.6M

Sector

Health Care

ML Signal

HOLD

Logo ENDRA Life Sciences Inc.

NDRA

ENDRA Life Sciences Inc.

HOLD

Current Price

$5.42

Market Cap

7.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NCNA
NDRA
Founded
1997
2007
Country
United Kingdom
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6M
7.3M
IPO Year
2017
2017

Fundamental Metrics

Financial Performance
Metric
NCNA
NDRA
Price
$3.72
$5.42
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$30.00
AVG Volume (30 Days)
65.1K
114.8K
Earning Date
11-13-2025
11-17-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.78
$2.90
52 Week High
$330.00
$11.96

Technical Indicators

Market Signals
Indicator
NCNA
NDRA
Relative Strength Index (RSI) 44.93 44.56
Support Level $4.10 $5.17
Resistance Level $4.55 $6.00
Average True Range (ATR) 0.28 0.64
MACD -0.01 -0.05
Stochastic Oscillator 7.06 20.59

Price Performance

Historical Comparison
NCNA
NDRA

About NCNA NuCana plc

NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.

About NDRA ENDRA Life Sciences Inc.

ENDRA Life Sciences Inc is engaged in the development of Thermo Acoustic Enhanced UltraSound (TAEUS) to visualize tissue like MRI at the cost and at the point of patient care. TAEUS is designed to work in concert with around 400,000 cart-based ultrasound systems in use globally today. TAEUS is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, the firm is exploring several other clinical applications of TAEUS, including visualization of tissue temperature during energy-based surgical procedures.

Share on Social Networks: